Article: Fed: Clamp down on perks as drug companies face more scrutiny

Article: Drug companies face backlash from new foes; ...
The Christian Science Monitor;  October 15, 2002 ;     700+ words ... ... industry. They charge that some of the drug companies' business practices are misleading ... warning two weeks ago that many of the drug companies' longstanding marketing practices ... guidance, was particularly concerned with drug companies hiring doctors and other healthcare ...

Article: Drug companies face research overhaul
Post-Tribune (IN);  December 9, 2006 ;     700+ words ... ... Lipitor (shown above), and other drug companies have justified the high prices they ... approvals(CHART) Pfizer Inc. and other drug companies have long justified the high prices ... conducts research for drugmakers. Drug companies increasingly use biomarkers, which ...

Article: Drug companies face increased scrutiny , The ...
Charleston Gazette;  September 27, 2004 ;     700+ words ... ... and antidepressants to encompass what drug companies reveal about their scientific studies ... the author of "The Truth About the Drug Companies," a recent book critical of the pharmaceutical ... announced that, starting next year, any drug companies that want to publish in those ...

Article: Drug companies face pricing challenges
Post-Tribune (IN);  November 20, 2005 ;     700+ words ... ... rein in pricing. Evans estimates the benefit could lower drug companies earnings by between 3 percent and 13 percent in 2008 and ... contend the benefit will only add to growing pressure on drug companies to prove that their products are more cost-effective than ...

Article: Patent remedies; Compulsory licensing.(Drug ...
The Economist (US);  October 27, 2001 ;     700+ words ...Drug companies are not alone in facing the risk of having patents taken away ANTHRAX ... needs, as long as it compensates the patent holder. Naturally, drug companies do not much like the prospect of losing their patents. As Jeff Kushan ...

Article: Drug companies face monetary penalties over ...
Medical Marketing & Media;  November 1, 2000 ;     694 words ...* Monetary penalties up to $250,000 for pharmaceutical company CEOs would be imposed for violations of proposed prescription drug reimportation legislation agreed to by House and Senate conferees in October. The aim of the legislation, supported by President Clinton but strongly opposed by

Article: DRUG COMPANIES FACE SCRUTINY OVER IMMUNE ...
The Columbian;  April 24, 1998 ;     569 words ...AP The Columbian 04-24-1998 WASHINGTON (AP) - The six companies that make immune globulin are under scrutiny from scientists and lawmakers to account for shortages of the medicine, vital to thousands of Americans, many of them children, with deficient immune systems. ``I think there is in fact on